Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594502 · ClinicalTrials.gov registry record
Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 139
- Enrollment target
NCT01594502: Completed study, sponsored by University of Illinois at Chicago.
NCT01594502 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01594502 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
Study Summary
The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.
Interventions
- DRUG Placebo
- DRUG Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-07 |
What the finished NCT01594502 record still lists
NCT01594502 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01594502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01594502 about?
NCT01594502 is a clinical study titled "Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies". The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemo...
What is the current status of trial NCT01594502?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2011-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01594502?
The interventions under investigation include: Placebo (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT01594502?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia